Stock market today: S&P 500 extends monthly win streak despite Nvidia-led stumble
Investing.com - UBS upgraded Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raised its price target to $30.00 from $20.00 as analyst coverage of the company changes hands. The company maintains a strong financial position with more cash than debt and a healthy current ratio of 6.0x.
The investment bank sees potential upside in Fulgent’s Precision Diagnostics segment, which represents approximately 60% of total sales, citing share gain opportunities in what it describes as a more favorable reimbursement landscape.
UBS notes that the company’s Anatomic Pathology business, accounting for roughly 35% of sales, has begun to recover and is no longer diluting growth for the diagnostic testing firm.
The firm expects Fulgent to maintain approximately 10% revenue growth in 2025 and beyond, which it believes aligns more closely with broader specialty and oncology peers based on its analysis, while suggesting current valuation gives the company no credit for this growth trajectory.
UBS also indicates investors may reassess the value of Fulgent’s pharmaceutical assets when data from the FID-007 trial becomes available in 2026.
In other recent news, Fulgent Genetics reported its Q2 2025 earnings, revealing a revenue of $81.8 million, which exceeded the forecast of $76.21 million. Despite the revenue beat, the company reported an earnings per share (EPS) of $0.07, which fell short of the expected EPS of $-0.18. This EPS result marked a surprise of -138.89%. These earnings results highlight the company’s mixed performance, with strong revenue figures but a miss on the EPS front. Investors might find the revenue performance encouraging, although the EPS miss could be a point of concern. There were no updates on any mergers or acquisitions involving Fulgent Genetics. Additionally, there were no recent analyst upgrades or downgrades reported for the company. These developments provide a snapshot of Fulgent Genetics’ current financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.